Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2D | Q13557 | 1/20 | 0.69 |
| ▸ | SYK | P43405 | 3/20 | 0.65 |
| ▸ | CLK1 | P49759 | 1/20 | 0.65 |
| ▸ | CLK2 | P49760 | 1/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.65 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.65 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.65 |
| ▸ | ABL1 | P00519 | 2/20 | 0.63 |
| ▸ | BCR | P11274 | 2/20 | 0.63 |
| ▸ | SRC | P12931 | 2/20 | 0.63 |
| ▸ | PLK1 | P53350 | 1/20 | 0.63 |
| ▸ | EGFR | P00533 | 1/20 | 0.63 |
| ▸ | PRKACA | P17612 | 1/20 | 0.63 |
| ▸ | PRKACG | P22612 | 1/20 | 0.63 |
| ▸ | PRKACB | P22694 | 1/20 | 0.63 |
| ▸ | AURKA | O14965 | 3/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.60 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.60 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30554563 | 1.00 | CAMK2D (0.69) | CAMK2DSYKCLK1CLK2DYRK1A | |
| SCHEMBL25337631 | 0.89 | PLK1 (0.72) | CAMK2DSYKCLK1CLK2DYRK1A | |
| SCHEMBL30554478 | 0.89 | PLK1 (0.72) | CAMK2DSYKCLK1CLK2DYRK1A | |
| SCHEMBL12801628 | 0.88 | CAMK2D (0.69) | CAMK2DSYKCLK1CLK2DYRK1A | |
| SCHEMBL823915 | 0.87 | CAMK2D (0.82) | CAMK2DSYKABL1BCRSRC | |
| SCHEMBL27119203 | 0.87 | AURKA (0.63) | CLK1CLK2DYRK1ACLK4DYRK1B | |
| SCHEMBL27115596 | 0.86 | SYK (0.65) | SYKCLK1CLK2DYRK1ACLK4 | |
| SCHEMBL27116471 | 0.84 | CLK1 (0.66) | CLK1CLK2DYRK1ACLK4DYRK1B | |
| SCHEMBL9014180 | 0.84 | ABL1 (0.68) | CLK1CLK2DYRK1ACLK4DYRK1B | |
| SCHEMBL4901590 | 0.84 | ABL1 (0.67) | CLK1CLK2DYRK1ACLK4DYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022099-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2026-01-22 | — | — | US | disclosed |
| US-12371408-B2 | Aryl hydrocarbon receptor agonists and uses thereof | NEXYS THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-12168646-B2 | Aryl hydrocarbon receptor agonists and uses thereof | NEXYS THERAPEUTICS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| EP-4472953-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | Nexys Therapeutics, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240279185-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | US | disclosed |
| US-20240208913-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208913-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208913-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2023150197-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023150197-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371408-B2 | Aryl hydrocarbon receptor agonists and uses thereof | AHR, ARNT, NR1H2 | CAMK2D 1708/4885SYK 3388/4885CLK1 4553/4885 |
| US-20260022099-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | AHR, NR1H4, CNR1 | CAMK2D 1919/4885SYK 3947/4885CLK1 3677/4885 |
| US-20240279185-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | AHR, ARNT, NR1H2 | CAMK2D 1708/4885SYK 3388/4885CLK1 4553/4885 |
| US-12168646-B2 | Aryl hydrocarbon receptor agonists and uses thereof | AHR, ARNT, NR1H2 | CAMK2D 1708/4885SYK 3388/4885CLK1 4553/4885 |
| US-20240208913-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | AHR, ARNT, NR1H2 | CAMK2D 1708/4885SYK 3388/4885CLK1 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.